Objective: To compare the intraocular pressure (IOP)-lowering effect and safety of topical brimonidine to that of timolol, and to study the additive effect of topical brimonidine to topical prostaglandin (PG) analogues in 475 patients with either ocular hypertension or primary open angle glaucoma.
Methods: The primary endpoint was the mean IOP change from the baseline at 0 and 2 hours at week 4.
Results: The mean changes were -4.7 +/- 2.1 (S. D.) in the timolol and -4.0 +/- 2.0 mmHg in the brimonidine group (p = 0.0138). The 95% confidence interval of the inter-group difference was greater than the pre-determined criterion of non-inferiority of brimonidine to timolol. When added to PG analogues, the IOP-lowering effect of brimonidine (-2.9 +/- 1.8 mmHg) was greater than that of the placebo (-2.1 +/- 1.8 mmHg) (p = 0.0010). No appreciable adverse side effects were encountered.
Conclusion: Topical brimonidine showed an additive IOP-lowering effect to topical PG analogues, although its IOP-lowering effect was inferior to topical timolol as monotherapy.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Randomized Clinical Trial of Intraocular Pressure-Lowering Medications on Preventing Spikes in Intraocular Pressure Following Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
Ophthalmol Ther
December 2024
Department of Ophthalmology, Mettapracharak (Wat Rai Khing) Hospital, 52 Moo 2 Rai Khing Sam Pran, Nakhon Pathom, 73210, Thailand.
Introduction: Intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents are a primary management option for retinal diseases. Acute elevation of intraocular pressure (IOP) is a complication associated with these injections that should be considered. This study investigated and compared the prophylactic effects of fixed combination anti-glaucoma medication on IOP spikes following intravitreal anti-VEGF injections.
View Article and Find Full Text PDFComparative analysis of medical treatments for long-term control of normal tension glaucoma: A systematic review and model-based network meta-analysis.
Clin Exp Ophthalmol
October 2024
Department of Ophthalmology, China Medical University Hospital, China Medical University, Taichung, Taiwan.
Background: To evaluate and compare the long-term efficacy of medical treatments for normal tension glaucoma (NTG) in controlling intraocular pressure (IOP), and establish a hierarchical ranking based on their effectiveness. 'Long-term' is defined as a treatment duration of over 12 weeks in randomised controlled trials (RCTs).
Methods: This systematic review and model-based network meta-analysis (MBNMA) collected data of 795 patients with 997 eyes from RCTs.
Anti-oxidative mesoporous polydopamine-based hypotensive nano-eyedrop for improved glaucoma management.
Colloids Surf B Biointerfaces
January 2025
State Key Laboratory of Ophthalmology, Optometry and Vision Science, School of Ophthalmology & Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325027, China; National Engineering Research Center of Ophthalmology and Optometry, Institute of Biomedical Engineering, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325027, China; National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325027, China. Electronic address:
Conventional hypotensive eye drops remain suboptimal for glaucoma management, primarily due to their limited intraocular bioavailability and the growing concern regarding ocular surface side effects. Therefore, there is an urgent need to develop innovative intraocular pressure (IOP)-lowering formulations that not only possess enhanced corneal penetration ability but also provide ocular surface protection. Herein, anti-oxidative mesoporous polydopamine nanoparticles (MPDA NPs) were explored as a nano-carrier for Brimonidine to address the above issues.
View Article and Find Full Text PDFA combination of topical and systemic administration of brimonidine is neuroprotective in the murine optic nerve crush model.
PLoS One
August 2024
Department of Ophthalmology, Academy of Medicine, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Article Synopsis
- - Glaucoma, a condition that damages retinal ganglion cells (RGC), was studied to evaluate the neuroprotective effects of brimonidine, which can lower intraocular pressure and potentially protect these cells.
- - In the experiment, 41 mice had their optic nerves crushed and were divided into three groups receiving different treatments: saline, topical brimonidine, or a combination of topical and intraperitoneal (IP) brimonidine injections.
- - Results showed that mice receiving both topical and IP brimonidine had significantly higher RGC survival rates compared to those receiving only saline or just topical brimonidine.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!